Biogen’s lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why ...

With its 2-star rating, we believe Lilly stock is overvalued compared with our long-term fair value estimate of $650 per ...

The European Commission has approved Eisai and Biogen's Leqembi for a subset of patients with early-stage Alzheimer's disease, setting it up to become the first amyloid-targeting drug to reach the ...

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...

Susan Aaron was an active 74-year-old retiree with Alzheimer’s who was told she might experience extreme fatigue and terrible headaches if she tried a new drug from Eisai Co. that promised to slow the ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...

Biogen BIIB will report first-quarter 2025 results on May 1, before market open. In the last reported quarter, the company's ...

Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and ...

A phase I/II trial showed that transplanting dopaminergic progenitors derived from induced pluripotent stem cells was safe in ...